Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart ablation technique aims to zap troubling rhythms

NCT ID NCT06747013

Disease control Sponsor: Vivek Reddy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study is testing a new type of catheter that uses pulsed electrical fields to treat certain heart rhythm problems, specifically premature ventricular contractions (PVCs) and ventricular tachycardia. The device, called Farapoint, is designed to map and ablate (destroy) the tiny areas of heart muscle causing the abnormal rhythms. Researchers will enroll 60 people and follow them for 3 months to see if the procedure reduces or eliminates these arrhythmias without needing more medication. The study also closely tracks any side effects or complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulsed field ablation catheter (Farapoint)
What this could lead to
If successful, this could provide a new, potentially safer way to treat certain heart rhythm problems without long-term medication.
What could go wrong
This is an early study with only 60 participants, so results may not apply to everyone. There are risks of serious side effects from the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet ALL of the following inclusion criteria to be eligible for participation in this clinical investigation: * Patient is planned for a catheter ablation procedure to ablate either: * Premature ventricular contractions (PVCs) and a class I or IIa indication for catheter ablation of PVCS according to the 2019 HRS/EHRA/APHRS/LAHRS guidelines * Symptomatic Sustained Monomorphic Ventricular Tachycardia * Able and willing to provide written consent and comply with all testing and follow-up requirements * Above 18 years of age Exclusion Criteria: * Documented intracardiac thrombus or (if this can be dissolved with anticoagulation, the patient would then be eligible to participate) * Contraindication to anticoagulation * Life expectancy or other disease processes likely to limit survival to less than 12 months. * Currently enrolled in an investigational study evaluating another device, biologic, or drug, that would interfere with this trial. * NYHA Class IV heart failure * Severe, untreated coronary artery disease which would preclude infusion of provocative agents * Severe aortic stenosis (AVA \< 1.0cm, or PG \> 64mmHg) * Severe mitral regurgitation. * Allergy to contrast which is unable to be adequately pre-medicated. * Acute non-cardiovascular illness or systemic infection * Thrombocytopenia (platelet count \< 50,000/mm3) or coagulopathy unless corrected * Cardiogenic shock unrelated to ventricular arrhythmias * Pregnancy or anticipated pregnancy during study follow-up * PVCs or VT, which are felt to be secondary to electrolyte imbalances active thyroid disease or any reversible non-cardiac cause.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal ventricular arrhythmias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ventricular Premature Complexes ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal ventricular arrhythmias Premature ventricular contractions Ventricular tachycardias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.